Millipore Sigma Vibrant Logo

MABC14 Anti-VHL Antibody, clone 11E12

This Anti-VHL Antibody, clone 11E12 is validated for use in WB, IP for the detection of VHL.

Anti-VHL Antibody, clone 11E12 MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Apoptosis & Cancer, Signaling Research Sub-Category: Tumor Markers, Ubiquitin & Ubiquitin Metabolism Gene Symbol: VHL, VHL1, HRCA1, RCA1, pVHL UniProt Number: P40337
View Products on Sigmaaldrich.com
MABC14
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Fulfillment and delivery delayed Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Special Offers

      100% Performance Guaranteed

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      M, HWB, IPMPurifiedMonoclonal Antibody
      Description
      Catalogue NumberMABC14
      DescriptionAnti-VHL Antibody, clone 11E12
      Alternate Names
      • von Hippel-Lindau disease tumor suppressor
      • Protein G7
      • elongin binding protein
      • von Hippel-Lindau syndrome
      • pVHL
      Background Informationvon Hippel-Lindau protein (VHL) is most widely recognized as belonging to an E3 ubiquitin ligase complex that specifically targets hypoxia-inducible factors (HIFs) for the purpose of polyubiquitination and proteolytic degradation. Within this complex, VHL acts as a target recruitment subunit for HIFα and its subsequent ubiquitination. The complex also contains proteins such as B and C elongins, Rbx1 and Cul2. Inactivation of VHL has been linked to renal cell carcinoma development, therefore suggesting that VHL plays a role as a tumor suppressor. VHL expression has been observed in both fetal and adult kidney and brain tissues. Defects in VHL expression are causal to renal cell carcinoma type 1 (RCC1), erythrocytosis familial type 2 (ECYT2), von Hippel-Lindau disease (VHLD), and pheochromocytoma.
      References
      Product Information
      FormatPurified
      Control
      • Mouse fetal brain tissue lysate
      PresentationPurified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationThis Anti-VHL Antibody, clone 11E12 is validated for use in WB, IP for the detection of VHL.
      Key Applications
      • Western Blotting
      • Immunoprecipitation
      Application NotesImmunoprecipitation: It has been shown that this VHL clone will immunoprecipitate VHL from HEK 293 cells (Shoenfeld, 1998).
      Biological Information
      ImmunogenPurified human VHL
      Clone11E12
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      IsotypeIgG1κ
      Species Reactivity
      • Mouse
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryVon Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].
      Gene Symbol
      • VHL
      • VHL1
      • HRCA1
      • RCA1
      • pVHL
      Purification MethodProtein G
      UniProt Number
      UniProt SummaryFUNCTION: Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.

      PATHWAY: Protein modification; protein ubiquitination.

      SUBUNIT STRUCTURE: Component of the VCB (VHL-Elongin BC-CUL2) complex; this complex acts as a ubiquitin-ligase E3 and directs proteosome-dependent degradation of targeted proteins. Interacts with CUL2; this interaction is dependent on the integrity of the trimeric VBC complex. Interacts (via the beta domain) with HIF1A (via the NTAD domain); this interaction mediates degradation of HIF1A in normoxia and, in hypoxia, prevents ubiqitination and degradation of HIF1A by mediating hypoxia-induced translocation to the nucleus, a process which requires a hypoxia-dependent regulatory signal. Interacts with RNF139 and UBP33. Interacts with PHF17.

      SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Note: Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated.

      Isoform 3: Cytoplasm. Nucleus. Note: Equally distributed between the nucleus and the cytoplasm but not membrane-associated.

      TISSUE SPECIFICITY: Expressed in the adult and fetal brain and kidney.

      DOMAIN: The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV].

      INVOLVEMENT IN IDSEASE: Defects in VHL are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown.

      Defects in VHL are the cause of von Hippel-Lindau disease (VHLD) [MIM:193300]. VHLD is a dominantly inherited familial cancer syndrome characterized by the development of retinal angiomatosis, cerebellar and spinal hemangioblastoma, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumors. VHL type 1 is without pheochromocytoma, type 2 is with pheochromocytoma. VHL type 2 is further subdivided into types 2A (pheochromocytoma, retinal angioma, and hemangioblastomas without renal cell carcinoma and pancreatic cyst) and 2B (pheochromocytoma, retinal angioma, and hemangioblastomas with renal cell carcinoma and pancreatic cyst). VHL type 2C refers to patients with isolated pheochromocytoma without hemangioblastoma or renal cell carcinoma. The estimated incidence is 3/100000 births per year and penetrance is 97% by age 60 years.

      Defects in VHL are the cause of erythrocytosis familial type 2 (ECYT2) [MIM:263400]; also called VHL-dependent polycythemia or Chuvash type polycythemia. ECYT2 is an autosomal recessive disorder characterized by an increase in serum red blood cell mass, hypersensitivity of erythroid progenitors to erythropoietin, increased erythropoietin serum levels, and normal oxygen affinity. Patients with ECYT2 carry a high risk for peripheral thrombosis and cerebrovascular events.

      Defects in VHL are a cause of renal cell carcinoma type 1 (RCC1) [MIM:144700]; also known as hypernephroma or adenocarcinoma of kidney. Familial renal cell carcinoma syndromes form a group of diseases characterized by a predisposition to development of renal cell carcinomas (RCCs) with various histological subtypes.
      Molecular Weight ~ 24 kDa observed MW. VHL SUMOylation may result in high MW bands (Cai, 2010).
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot in mouse fetal brain tissue lysate.

      Western Blot Analysis: 1 µg/mL of the antibody detected VHL in 10 µg of mouse fetal brain tissue lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      MABC14 04053252480515

      Documentation

      Anti-VHL Antibody, clone 11E12 SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-VHL Antibody, clone 11E12 Certificates of Analysis

      TitleLot Number
      Anti-VHL, clone 11E12 - 2385972 2385972
      Anti-VHL, clone 11E12 - 2448429 2448429
      Anti-VHL, clone 11E12 - 2205008 2205008
      Anti-VHL, clone 11E12 - 2291726 2291726
      Anti-VHL, clone 11E12 - 3231940 3231940
      Anti-VHL, clone 11E12 - 3454413 3454413
      Anti-VHL, clone 11E12 - 3683198 3683198
      Anti-VHL, clone 11E12 - 3692732 3692732
      Anti-VHL, clone 11E12 - 3879524 3879524
      Anti-VHL, clone 11E12 - NRG1786872 NRG1786872
      Show more